New Research Publication: OliFuco® Oligo Fucoidan Attenuates Cardiac Remodeling by Inhibiting Galectin-3 Secretion, Fibrosis, and Inflammation in a Mouse Model of Pressure Overload

Dr. Wen-Rui Hao from the Division of Cardiology, Shuang Ho Hospital, has led groundbreaking research using Hi-Q's innovative ingredient, OliFuco®. The study results have been published in the prestigious journal Biomedicines. 🩺

🔷 Title of the Study:

Fucoidan Attenuates Cardiac Remodeling by Inhibiting Galectin-3 Secretion, Fibrosis, and Inflammation in a Mouse Model of Pressure Overload.

✅ Key Findings:

The research revealed that fucoidan effectively mitigates the adverse effects of pressure overload in a mouse model, significantly reducing Galectin-3 expression, fibrosis, and inflammation. These promising results highlight fucoidan’s potential in preventing or delaying cardiac remodeling and associated complications, such as fibrosis and inflammation, in pressure overload-induced cardiac hypertrophy.

A heartfelt thank you to Dr. Hao for his dedication and contributions to advancing cardiovascular science. His research inspires us to keep striving for innovation and health improvement! ❤️ 

As 2024 comes to a close, we wish everyone a joyful and healthy New Year. Let’s step into 2025 with full hearts, embracing hope and determination to build a healthier, brighter future together. 💗 

From our hearts to yours, Happy New Year! ❤️